Drug Discovery and Development🔒 SSL Verified

Table of Contents

• ↓ Pharma commercial vendor selection still runs on word of mouth. A Harvard MBA student aims to change that with Rx Almanac.
• ↓ After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
• ↓ DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
• ↓ Search Drug Discovery & Development
• ↓ Top Alternatives to drugdiscoverytrends.com

6-Month Traffic Trend Estimate

Official Contact & Profiles

Visual representation extracted from drugdiscoverytrends.com

Content Snippets from drugdiscoverytrends.com

"The Arlington, Virginia–based nonprofit American Association of Pharmaceutical Scientists (AAPS) will launch two Innovator-Curated tracks at its 2026 PharmSci 360 conference, scheduled for October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The organization announced that the tracks will explore the current state of scientific research integrity in an AI…"

"Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…"

"The COVID-19 pandemic left most of the world’s population with an immune memory for COVID. A Cleveland-based biotech wants to use that memory to fight cancer. Celloram, a preclinical stage company focusing on therapies for cancer, autoimmune diseases and chronic inflammatory and metabolic disorders, in partnership with Case Western Reserve University and University Hospitals Cleveland Medical Center, published preclinical results for a…"

"The magic mushroom compound psilocybin, which has had favorable results in two Phase 3 trials of depression and could be available as soon as 2027, has shown promise in rodents as a potential preventative for Chemotherapy‑Induced Peripheral Neuropathy (CIPN), a disabling pain condition caused by chemotherapy that affects about 30% to 50% of patients receiving chemotherapy. A 2014 review found that 68.1% of chemotherapy patients across 31 studies had CIPN when measured in…"

Key Topics & Focus Areas for drugdiscoverytrends.com:

Pharma commercial vendor selection still runs on word of mouth. A Harvard MBA student aims to change that with Rx Almanac.

After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice

DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I

Search Drug Discovery & Development